AbbVie (id:8478 ABBV)
177.37 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 2:31:03 PM)
Exchange open, closes in 1 hour 28 minutes
About AbbVie
Market Capitalization 310.93B
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Headquarters (address) |
1 North Waukegan Road North Chicago 60064-6400 IL United States |
| Phone | 847 932 7900 |
| Website | https://www.abbvie.com |
| Employees | 50K |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | ABBV |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 153.58 - 207.32 |
| Market Capitalization | 310.93B |
| Dividend yield forward | 3.53 % |
| Dividend yield forward United States (ID:6, base:1858) | 4.48 % |
| P/E trailing | 61.52 |
| P/E forward | 14.51 |
| Price/Sale | 5.60 |
| Price/Book | 51.55 |
| Beta | 3.00 |
| EPS | 2.86 |
| EPS United States (ID:6, base:3382) | 24.33 |
Dividend growth streak
AbbVie has raised their dividend 10.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: AbbVie has raised their dividend 3.53 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: AbbVie has raised their dividend 7.84 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: AbbVie has raised their dividend 10.52 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: AbbVie has raised their dividend 13.98 years in a row. This is above the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: AbbVie has raised their dividend 213.59 years in a row. This is above the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
AbbVie years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
AbbVie has raised their dividend 10.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: AbbVie has raised their dividend 3.53 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: AbbVie has raised their dividend 7.84 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: AbbVie has raised their dividend 10.52 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: AbbVie has raised their dividend 13.98 years in a row. This is above the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: AbbVie has raised their dividend 213.59 years in a row. This is above the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
AbbVie years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry